NCT00408863View on ClinicalTrials.gov

Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885)

PHASE3CompletedINTERVENTIONAL

Enrollment

3,148

Participants

Timeline

Start Date

May 31, 2002

Primary Completion Date

October 31, 2007

Study Completion Date

October 31, 2007

Conditions

Breast CancerClimacteric Symptoms

Interventions

DRUG

tibolone

tibolone 2.5 mg/day

DRUG

placebo

All Listed Sponsors

lead

Organon and Co

INDUSTRY

NCT00408863 - Livial Intervention Following Breast Cancer; Efficacy, Recurrence and Tolerability Endpoints (LIBERATE)(COMPLETED)(P05885) | Biotech Hunter | Biotech Hunter